Latest Breaking News On - அமலாக்கம் அறிக்கை - Page 1 : vimarsana.com

Cipla recalls 7,228 bottles of overactive bladder treatment drug in America SECTIONS Last Updated: Jul 25, 2021, 12:27 PM IST Share Synopsis As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. ThinkStock Photos Drug major Cipla is recalling 7,228 bottles of Solifenacin Succinate tablets, a medicine used to treat overactive bladder, in the US market due to manufacturing issues. As per the latest Enforcement Report issued by the US Food and Drug Administration (USFDA), the Mumbai-based company is recalling 10 mg, 30-count bottles in the US.

Drug administrationCipla united states incSolifenacin succinateEnforcement reportNew jersey basedCipla united statesசிப்லா ஒன்றுபட்டது மாநிலங்களில் இன்க்அமலாக்கம் அறிக்கைபுதியது ஜெர்சி அடிப்படையிலானதுசிப்லா ஒன்றுபட்டது மாநிலங்களில்